Neuropacs Announces the Publication of a New Study Comparing the First-of-Its-Kind FDA De Novo–Classified Imaging Biomarker for Parkinson’s Disease With CSF Alpha-Synuclein Seed Amplification Assay (Business wire)
UF startup Neuropacs announced new research highlighting its AI-powered Parkinson’s diagnostic technology, which recently received FDA clearance for clinical use.
Rise Therapeutics Completes Enrollment in Four-Week Dose Expansion Cohort for the R-2487 Rheumatoid Arthritis Clinical Trial (PR Newswire)
UF startup Rise Therapeutics has completed enrollment in a Phase 1b clinical trial evaluating its oral immunotherapy candidate for patients with active rheumatoid arthritis.
Myosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-Muscle Myosin II in Newly Diagnosed Glioblastoma (PR Newswire)
UF startup Myosin Therapeutics has dosed the first patient in its Phase 1/2 glioblastoma trial, advancing the development of a potential new cancer therapy in collaboration with the Mayo Clinic and NCI.
Atsena Therapeutics Receives Data Monitoring Committee Recommendation To Proceed With Pivotal Part C Cohort of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients With X-Linked Retinoschisis (Globe Newswire)
UF startup Atsena Therapeutics has been cleared to advance to the pivotal phase of its LIGHTHOUSE trial for a gene therapy targeting X-linked retinoschisis, with patient screening set to begin this month.
INZECTO Awarded Pest Control Products Development Company of the Year 2026 (Environmental Business Review)
UF startup INZECTO has been awarded the Pest Control Products Development Company of the Year 2026 by Environmental Business Review.
LightPath Technologies Receives $9.6 Million Purchase Order for Cooled Infrared Cameras From Existing Defense Customer (PR Newswire)
UF startup LightPath Technologies, Inc., announced that it has secured a $9.6 million purchase order for cooled infrared cameras from an existing defense customer for use in defense and security applications, with deliveries expected throughout calendar year 2026.
Grant Glues Together Research Experts To Tackle Incurable Diseases (The Wertheim UF Scripps Institute)
UF researcher Thomas Kodadek’s team has won a prestigious international grant to collaborate with Merck KGaA on developing “molecular glue degraders,” a novel technology that harnesses the body’s recycling system to treat previously undruggable diseases like aggressive cancers and brain disorders.
Scientists Say These Two Viruses May Become the Next Public Health Threats (UF Health)
A study co-authored by UF’s Dr. John Lednicky identifies influenza D and canine coronavirus as emerging respiratory threats, citing a critical need for UF-led surveillance to prevent potential spillover events.
LightPath Technologies Acquires Amorphous Materials, Inc. (PR Newswire)
UF startup LightPath Technologies, Inc. announced it has acquired the assets of Amorphous Materials, Inc., which is an industrial manufacturer with complementary Chalcogenide glass melting technologies.
Genezen and Atsena Therapeutics Announce Strategic Commercial Manufacturing Partnership (PR Newswire)
UF startup Atsena Therapeutics and Genezen announced a manufacturing partnership to support the clinical development and future production of Atsena’s gene therapies for inherited retinal diseases.